Utility of a Nurse-Led Pathway for Patients with Acute Venous Thromboembolism Discharged on Rivaroxaban: A Prospective Cohort Study.
Acute Disease
Adult
Aged
Critical Pathways
Factor Xa Inhibitors
/ adverse effects
Female
Hemorrhage
/ chemically induced
Humans
Male
Middle Aged
Monitoring, Physiologic
/ methods
Nurse-Patient Relations
Outcome Assessment, Health Care
/ methods
Prospective Studies
Recurrence
Risk Factors
Rivaroxaban
/ adverse effects
Venous Thromboembolism
/ prevention & control
Journal
Seminars in thrombosis and hemostasis
ISSN: 1098-9064
Titre abrégé: Semin Thromb Hemost
Pays: United States
ID NLM: 0431155
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
pubmed:
20
12
2018
medline:
2
4
2019
entrez:
20
12
2018
Statut:
ppublish
Résumé
The highest risk of adverse events for patients with acute venous thromboembolism (VTE) is during the early anticoagulation period. However, no established model exists for early clinical monitoring of patients treated with non-vitamin K antagonist oral anticoagulants (NOACs). The authors' aim was to evaluate the utility of a nurse-led pathway to minimize adverse events in acute VTE patients starting on rivaroxaban. The rivaroxaban VTE treatment pathway is a prospective cohort study of consecutive patients with objectively confirmed VTE between July 2015 and May 2017. Primary outcome was the proportion of patients identified at major risk of adverse events (bleeding or recurrent VTE). Secondary outcomes were rates of interventions, major or clinically relevant nonmajor bleeding (CRNMB), recurrent VTE, and all-cause mortality at 90 days. Among 304 participants, 5% (
Identifiants
pubmed: 30566971
doi: 10.1055/s-0038-1676320
doi:
Substances chimiques
Factor Xa Inhibitors
0
Rivaroxaban
9NDF7JZ4M3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
187-195Informations de copyright
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
Déclaration de conflit d'intérêts
T. Indran and A. Bennett received honorarium from Bayer during the conduct of the study. S. Chunilal received honorarium and consultancy fees from Bayer during the conduct of the study. H. Tran received honorarium from Bayer, Pfizer, Bristol Myers Squibb, and Boehringer Ingelheim unrelated to the conduct of the study. N.C. Chan received honorarium from Bayer outside the submitted work. All other authors declare no conflict of interests.